ASCO President-Elect Julie Vose, MD, MBA

2015 ASCO Annual Meeting

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, reflects on the 2015 Annual Meeting and her year ahead as ASCO President.

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).

Global Cancer Care

Cost of Care

John Smyth, MD

John Smyth, MD, on The Current State of Cancer Research and Treatment: The European Perspective

John Smyth, MD, of the University of Edinburgh, discusses oncology from an international point of view.

Head and Neck Cancer

Anil D’Cruz, MD

Anil D'Cruz, MD, on Elective Neck Dissection in Node-Negative Early Oral Cancer

Anil D’Cruz, MD, of Tata Memorial Hospital, discusses results from his study that seem to resolve a 50-year-long debate on performing elective neck dissection at the time of primary surgery––a potentially practice-changing finding (Abstract LBA3).

Colorectal Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

Breast Cancer

Julie Gralow, MD and Clifford A. Hudis, MD

Julie Gralow, MD, and Clifford A. Hudis, MD, on Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer

Julie Gralow, MD, of the University of Washington/Seattle Cancer Care Alliance, and Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, discuss this important SWOG trial and why oral bisphosphonates should be made available in the United States (Abstract 503).

May

Today In Oncology

ASCO President-Elect Julie Vose, MD, MBA

Related Videos

Daniel A. Vorobiof, MD, and Bernardo Leon Rapoport, MD, on NK-1 Inhibitors for CINV: Potentially Practice-Changing Data

John Smyth, MD, on The Current State of Cancer Research and Treatment: The European Perspective

Anil D'Cruz, MD, on Elective Neck Dissection in Node-Negative Early Oral Cancer

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Julie Gralow, MD, and Clifford A. Hudis, MD, on Bisphosphonates as Adjuvant Therapy in Primary Breast Cancer

FDA Approves Durvalumab Plus BCG for High-Risk NMIBC

Local Radiotherapy May Help Control Oligometastatic Breast Cancer

TAILORx and RxPONDER Trials Shift to a Discovery Platform

Radiotherapy for Prostate Cancer: HERMES Trial Compares Two and Five Fractions

BPDCN FDA Approves Pivekimab Sunirine-pvzy